Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Canagliflozin

These articles are all highly relevant Canagliflozin. I believe this information can help you understand Canagliflozin's professional information. If you want to know more, you can contact us at any time, we can provide you with more professional guidance.
  • Drug Patent & Exclusivity Expiration Report - Week of April 07 2025

    2025-04-07

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's INVOKAMET, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKAMET XR, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKANA, containing active ingredient CANAGLIFLOZIN - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - EISAI INC's DAYVIGO, containing active ingredient LEMBOREXANT - NOVARTIS PHARMACEUTICAL CORP's AFINITOR DISPERZ, containing active ingredient EVEROLIMUS - ASTRAZENECA PHARMACEUTICALS LP's KOSELUGO, containing active ingredient SELUMETINIB SULFATE Read More